The central hypothesis of this study is that targeted inhibition of MMP12 disrupts key oncogenic networks, as measured by specific genomic biomarkers, leading to suppressed lung cancer cell growth and metastatic potential. This evidence concerns the gene MMP12 and lung carcinoma.